Login to Your Account



SuperGen's Good News, Bad News

FDA Turns Down Orathecin, Reviews NDA For Dacogen

By Randall Osborne


Wednesday, January 5, 2005
Bad tidings from the FDA regarding SuperGen Inc.'s Orathecin for pancreatic cancer overshadowed positive (if expected) news about the company's Dacogen for myelodysplastic syndromes, partnered with MGI Pharma Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription